---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-068584"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:32:51.813174+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# ARS Pharmaceuticals updates corporate presentation; no material new details disclosed

## Summary
- Filed a Form 8-K on March 13, 2023, to furnish an updated corporate presentation.
- Presentation highlights neffy as 'first no-needle, no-injection solution' for Type I allergic reactions.
- No financial, clinical, or regulatory milestones were reported in the filing or the title slide of Exhibit 99.1.
- Presentation is available on the company's website; content beyond the title slide is not provided.

## SEC filing metadata
- accession: 0001193125-23-068584
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312523068584/0001193125-23-068584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312523068584/d444956d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-068584
- JSON: https://secwatch.observer/filing/0001193125-23-068584.json
- Plain text: https://secwatch.observer/filing/0001193125-23-068584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.